Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis

doi:10.3969/j.issn.2095-4344.2016.33.005

Abstract

Abstract:

BACKGROUND: Salmon calcitonin or elcatonin has been reported to alleviate acute and severe back pain caused by osteoportic fracture.
OBJECTIVE: To evaluate the effects of the combined use of elcatonin and risedronate in the treatment of chronic back pain and the improvement of quality of life in postmenopausal women with osteoporosis.
METHODS: Forty-five postmenopausal women with osteoporosis accompanied by chronic back pain persisting for more than 3 months, after excluding women with fresh vertebral fractures within the last 6 months, were randomly assigned to a risedronate group (administration of risedronate alone, n=22) and a combined drug group (combined administration of risedronate and elcatonin, n=23). Pain was evaluated using a visual analogue scale (VAS) and the Roland-Morris questionnaire. Bone mineral density was determined by dual-energy X-ray. Quality of life was assessed using the Medical Outcomes Study 36-Item Short-Form (SF-36) at 6 months after treatment.
RESULTS AND CONCLUSION: There were 20 and 19 cases in the risedronate and combined drug groups, respectively included in the final analysis. Significant improvements were found in the combined drug group for VAS and mental health status section scores in the SF-36 at final follow-up compared with baseline and 3-month follow-up, while no change was found in the risedronate group. Bone mineral density was increased significantly in both groups, while no significant difference was found between groups. These findings suggest that the use of elcatonin in addition to risedronate for more than 3 months may reduce chronic back pain in osteoporosis patients.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Calcitonin, Diphosphonates, Osteoporosis, Pain, Tissue Engineering

CLC Number:

R318

Liu Zhen-yu. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(33): 4899-4904.

Figures/Tables 4

References

[1] 陈小青,陈明珠,曾荣东.利塞膦酸钠治疗绝经后老年女性骨质疏松症临床研究[J]. 海峡药学, 2014, 26(2):97-99.
[2] Meschia M, Brincat M, Barbacini P, et al.A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bonemass in early postmenopausal women. Calcif Tissue Int. 1993;53(1):17-20.
[3] MellerI. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study. Calcif Tissue Int. 1986;39(6):416-417.
[4] Muñoz-Torres M, Alonso G, Raya MP.Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004;3(2):117-132.
[5] 刘强,孙佳,牛秀.依降钙素治疗老年骨质疏松症的临床疗效观察[J].中国实用医药, 2015, 10(1):6-7.
[6] Plosker GL,McTavish D.Intranasalsalcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.Drugs Aging. 1996;8(5):378-400.
[7] Fujita T, Ohue M, Nakajima M, et al.Comparison of the effects of elcatonin and risedronateonback and knee pain by electroalgometry using fall of skinimpedance and quality of life assessment using SF-36. J Bone Miner Metab. 2011;29(5):588-597.
[8] Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronicpain of recent and remote osteoporotic vertebral compressionfractures: a systematic review and meta-analysis. Osteoporos Int. 2012;23(1):17-38.
[9] Wells G, Cranney A, Peterson J, Boucher M, et al. Risedronate for the primary andsecondary prevention of osteoporotic fractures in postmenopausalwomen. Cochrane Database Syst Rev. 2008;23(1):CD004523.
[10] Takakuwa M, Iwamoto J. Elcatonin in combination withrisedronate is more effective than risedronate alone for relievingback pain in postmenopausal women with osteoporosis. Biol Pharm Bull. 2012;35(7): 1159-1165.
[11] 中华医学会风湿病学分会. 原发性骨质疏松诊治指南(2011年)[J]. 柳州医学, 2012, 25(3):188-199.
[12] Kumamoto K, Nakamura T, Suzuki T, et al.Validation of the Japanese Osteoporosis Quality of Life Questionnaire.J Bone Miner Metab. 2010;28(1):1-7.
[13] Miyakoshi N, Itoi E, Kobayashi M, et al. Impactofpostural deformities and spinal mobility on quality of life inpostmenopausal osteoporosis. Osteoporos Int. 2003;14(12):1007-1012.
[14] Lyritis GP, TrovasG.Analgesic effects of calcitonin. Bone. 2002;30(5 Suppl):71S-74S.
[15] Abellan Perez M, Bayina Garcia FJ, Calabozo M, et al.Multicenter comparative study of synthetic salmon calcitoninadministered nasally in the treatment of establishedpostmenopausal osteoporosis. An Med Interna.1995;12(1):12-16.
[16] Wysowski DK, Chang JT.Alendronate and risedronate:reports of severe bone, joint, and muscle pain. Arch Intern Med.2005;165(3):346-347.
[17] Nakamura T, Osawa M, Itoh M, et al.The effect of risedronate (17.5 mg/week) treatment onquality of life in Japanese women with osteoporosis: a prospectiveobservational study. J Bone Miner Metab. 2012;30(6):715-721.
[18] Hadji P, Zanchetta JR, Russo L, et al.Theeffect of teriparatide compared with risedronate on reduction ofback pain in postmenopausal women with osteoporotic vertebralfractures. Osteoporos Int. 2012; 23(8):2141-2150.
[19] Papadokostakis G, Damilakis J, Mantzouranis E, et al.The effectiveness of calcitonin on chronicback pain and daily activities in postmenopausal women withosteoporosis. Eur Spine J. 2006;15(3):356-362.
[20] Pontiroli AE, Pajetta E, Scaglia L, et al. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study. Aging (Milano). 1994;6(6):459-463.
[21] Quinlan J, Acute pain management in patients with persistent pain[J]. CurrOpin Support Palliat Care. 2012, 6(2):188-193.
[22] Ito A,Kumamoto E, Takeda M, et al.Mechanisms for ovariectomy-induced hyperalgesiaandits relief by calcitonin: participation of 5-HT1A-like receptor onC-afferent terminals in substantiagelatinosa of the rat spinal cord.J Neurosci. 2000;20(16):6302-6308.
[23] Yoshimura M, Furue H,Ito A.Mechanism of antinociceptive action of calcitonin--involvement of descending serotonergic system.Nihon Rinsho. 2005; 63 Suppl 10:211-213.
[24] Ofluoglu D, Akyuz G, Unay O, et al.The effect ofcalcitonin on beta-endorphin levels in postmenopausal osteoporoticpatients with back pain. Clin Rheumatol. 2007;26(1):44-49.
[25] Ringe JD, Farahmand P, Schacht E, et al.Superiorityof a combined treatment of Alendronate and Alfacalcidolcompared to the combination of Alendronate and plain vitamin DorAlfacalcidol alone in established postmenopausal or maleosteoporosis (AAC-Trial).Rheumatol Int. 2007;27(5):425-434.
[26] Itoh S, Sekino Y, Shinomiya K, et al.The effects ofrisedronate administered in combination with a proton pumpinhibitor for the treatment of osteoporosis. J Bone Miner Metab.2013;31(2):206-211.
[27] van Schoor NM, Smit JH, Twisk JW, et al. Impactofvertebral deformities, osteoarthritis, and other chronic diseases onquality of life: a population-based study.Osteoporos Int.2005; 16(7):749-756.